Assessing the efficacy of vasculoprotective dapagliflozin treatment in septic shock patients with microcirculatory dysfunction (GLIFLOSHOCK)
Septic shock is a life-threatening medical emergency caused by a severe infection. It causes blood pressure to drop dangerously low and harms blood flow through tiny vessels that feed vital organs. The GLIFLOSHOCK trial is testing a medicine called dapagliflozin (brand name Forxiga) to see if it can help protect these small vessels. Adult patients in hospital with septic shock will be given either dapagliflozin or a dummy treatment (placebo), alongside standard intensive care. The study aims to find out if the medicine helps patients come off blood-pressure support drugs sooner, lowers the need for kidney dialysis, and improves survival chances up to 28 days. Everyone in the trial continues to receive full standard medical care.
At a glance
What is this study about?
When the body has an extreme reaction to an infection, it can lead to a condition known as sepsis. In severe cases, this develops into septic shock. During septic shock, blood pressure falls sharply, and the body's tiniest blood vessels struggle to deliver oxygen to vital organs such as the heart and kidneys. Patients need urgent treatment in an intensive care unit (ICU), often requiring special medicines to raise their blood pressure and machines to support their organs.
Dapagliflozin is a medicine already used to treat diabetes, heart failure, and chronic kidney disease. Scientists believe it may also help shield and strengthen tiny blood vessels during severe infections, preventing them from leaking or failing. This study, called GLIFLOSHOCK, is designed to see if adding dapagliflozin to standard emergency care can protect these blood vessels and improve recovery.
Finding new ways to treat septic shock is critical because it remains one of the most dangerous conditions seen in hospitals. If dapagliflozin proves effective, it could help patients recover more quickly, shorten their stay in intensive care, and ultimately save lives.
Key takeaways
- The trial tests whether dapagliflozin helps protect blood vessels during septic shock.
- It is aimed at adults aged 18 and older who are receiving intensive care for severe infection.
- Participants receive either the study drug or a dummy pill (placebo) alongside full standard hospital care.
- Doctors will track recovery, kidney health, and survival over a 28-day period.
- Participation is voluntary, and standard treatment is never withheld.
Who may be eligible?
This study is for adults aged 18 and over who have been admitted to hospital with septic shock. To be considered, patients must show signs that their tiny blood vessels are struggling to supply enough blood and oxygen to their organs, and they must be receiving medicines to support their blood pressure.
Because septic shock is a sudden, critical emergency, patients are usually already in an intensive care setting when eligibility is assessed. Both men and women can take part.
People might not be eligible if they have certain pre-existing medical conditions, severe allergies to the study drug, or if the medical team decides that taking part would not be safe for them. The clinical team will review each patient's health records very carefully before enrolling them.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Aged 18 or older
- Currently in hospital with septic shock
- Receiving medications to support blood pressure
- Showing signs of poor blood flow in tiny blood vessels
- No known medical reasons or allergies that prevent taking dapagliflozin
What does participation involve?
Because this trial takes place in hospital, taking part does not require any extra travel or clinic visits. Eligible patients are randomly placed into one of two groups: one group receives a daily dose of dapagliflozin (10 mg), and the other group receives a matching dummy tablet (placebo). The treatment is given by mouth or through a feeding tube if the patient cannot swallow.
Patients continue to receive all their standard intensive care treatments, such as antibiotics, fluids, and breathing support. Doctors and nurses will closely monitor blood pressure, kidney function, and blood tests as part of routine hospital care.
The main observation period lasts for 28 days, or until the patient is well enough to be discharged from hospital. Doctors will specifically check how quickly blood pressure stabilises and whether kidney dialysis is needed.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is dapagliflozin normally used for?
Dapagliflozin is commonly prescribed for type 2 diabetes, heart failure, and chronic kidney disease to protect the heart and kidneys.
Will taking part replace normal sepsis treatment?
No. All patients will receive standard, full intensive care treatment, including antibiotics and fluids. The study tablet is given in addition to standard care.
What is a placebo?
A placebo is a dummy pill that looks just like the real medicine but contains no active ingredient. It helps researchers fairly test whether the real drug works.
How can someone join if they are too unwell to give consent?
In emergency intensive care research, strict legal safeguards allow doctors to seek agreement from a family member, partner, or legal representative until the patient is well enough to decide for themselves.
How long will the study last for each person?
Each participant is monitored while in hospital for up to 28 days, or until they are safely discharged home.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.